Hopes build over Gilead drug as global case count grows

An experimental antiviral drug to treat COVID-19 patients has fanned high expectations in the fight against the coronavirus pandemic, which has gained a decisive foothold in the United States and continues to spread around the world.

Gilead Sciences (GILD) acknowledged Wednesday that its drug, remdisivir, has seen positive results in both a company-sponsored and National Institute of Health-run study — with the federal regulators reportedly prepared to bestow emergency approval on the drug, according to The New York Times.

The treatment has been a frontrunner in the treatment race for...